Page last updated: 2024-08-26

bismuth and levofloxacin

bismuth has been researched along with levofloxacin in 65 studies

Research

Studies (65)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (12.31)	29.6817
2010's	37 (56.92)	24.3611
2020's	20 (30.77)	2.80

Authors

Authors	Studies
Cammarota, G; Candelli, M; Carloni, E; Cazzato, IA; Cremonini, F; Di Caro, S; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Ojetti, V; Santarelli, L; Zocco, MA	1
Andriulli, A; Barberani, F; Festa, V; Merla, A; Perri, F; Pilotto, A	1
Gisbert, JP; Morena, F	1
Benito, LM; Bermejo, F; Bory, F; Castro-Fernández, M; Cosme, A; Ducons, J; Fernández-Bermejo, M; Gisbert, JP; Lamas, E; López-Rivas, L; Olivares, D; Pabón, M; Pérez-Aisa, A	1
Chey, WD; Kim, HM; Saad, RJ; Schoenfeld, P	1
Pistiolas, D; Robotis, J; Rokkas, T; Sechopoulos, P	1
Gisbert, JL; Gisbert, JP; Marcos, S; Moreno-Otero, R; Pajares, JM	1
Fernández-Bermejo, M; Gisbert, JP; González-García, G; Mateos-Rodríguez, JM; Molina-Infante, J; Pérez-Gallardo, B; Prieto-Bermejo, AB; Robledo-Andrés, P	1
Hibi, T; Nishizawa, T; Suzuki, H	1
Huang, X; Li, Y; Shi, R; Yao, L; Zhang, G	1
Chuah, SK; Hsu, PI; Tsay, FW; Wu, DC	1
Buzás, GM	1
Gisbert, JP; Marin, AC; McNicholl, AG	1
Graham, DY; Liang, X; Liao, J; Liu, W; Lu, H; Sun, Q; Xiao, S; Zhang, W; Zheng, Q	1
Chen, A; Chen, WC; Hsu, PI; Kao, SS; Kuo, CH; Lai, KH; Peng, NJ; Shih, CA; Tsay, FW; Tseng, HH; Wang, HM; Wu, DC; Yu, HC	1
Ang, TL; Song, M	1
Heo, J; Jeon, SW	1
Aisa, AP; Barrio, J; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Gisbert, JL; Gisbert, JP; Marcos, S; Marín, AC; McNicholl, AG; Modolell, I; Molina-Infante, J; Rodrigo, L	1
Malfertheiner, P; Selgrad, M	1
Algaba, A; Angueira, T; Barrio, J; Bermejo, F; Castro-Fernández, M; Del Castillo, F; Domínguez, JL; Federico, A; Fernández-Salazar, L; Gisbert, JP; Gómez, B; Gómez, J; Gravina, AG; Herranz, M; Lucendo, AJ; Marín, AC; Martorano, M; McNicholl, AG; Miranda, A; Modolell, I; Molina-Infante, J; Ortuño, J; Pabón, M; Romano, M; Solís-Muñoz, P; Velayos, B	1
Cao, Z; Chen, Q; Liang, X; Liao, J; Liu, W; Lu, H; Xiao, S; Zhang, W	1
Graham, DY; Lu, H	1
Gisbert, JP; Molina-Infante, J; Romano, M	1
Mahachai, V; Prapitpaiboon, H; Vilaichone, RK	1
Annibale, B; Calabrese, C; Caselli, M; Di Mario, F; Farinati, F; Gasbarrini, G; Gullini, S; Ierardi, E; Luzza, F; Maconi, G; Ojetti, V; Pretolani, S; Romano, M; Rugge, M; Savio, A; Stockbrugger, R; Zagari, RM	1
Bai, P; He, L; Song, Z; Xue, Y; Zhang, J; Zhou, L	1
Hwang, JC; Kang, JK; Kim, JH; Kim, SS; Lee, KM; Lim, SG; Park, RW; Shin, SJ; Yoon, D	1
Chiba, N; Fallone, CA; Fischbach, L; Gisbert, JP; Hunt, RH; Jones, NL; Leontiadis, GI; Marshall, JK; Moayyedi, P; Render, C; van Zanten, SV	1
Chey, WD; Howden, CW; Leontiadis, GI; Moss, SF	1
Chen, H; Hao, B; Su, J; Zhang, G; Zhang, W; Zhou, X	1
Gisbert, JP; Marin, AC; McNicholl, AG; Nyssen, OP	1
Ding, Y; Fu, W; Song, Z; Suo, B; Tian, X; Wang, L; Xue, Y; Zhou, L	1
Chen, CY; Lyu, B; Wang, XT; Zhang, M	1
Hu, Y; Lu, NH; Zhu, Y	1
Ang, D; Ang, TL; Chew, CA; Lye, TF	1
Chen, A; Cheng, JS; Chuah, SK; Hsu, PI; Hsu, WH; Hu, HM; Kao, SS; Peng, NJ; Tsai, FW; Tsai, KW; Wang, YK; Wu, DC	1
Bellesia, A; De Francesco, V; Palma, R; Panetta, C; Pontone, S; Serviddio, G; Zullo, A	1
Göktaş, Z; Kahramanoğlu Aksoy, E; Nazlıgül, Y; Pirinçci Sapmaz, F; Uzman, M	1
De Francesco, V; Vaira, D; Zullo, A	1
Chan, EW; Chen, L; Cheung, KS; Graham, DY; Leung, WK; Wong, AYS; Wong, ICK; Wong, IOL; Yeung, KF	1
Gan, HY; Huang, YM; Peng, TL; Su, KH; Yang, RJ; Yao, LY; Zhao, LL	1
Chen, PY; Kuo, YT; Liou, JM; Wu, MS	1
Fallone, CA; Malfertheiner, P; Moss, SF	1
Chen, Q; Chen, Y; Gao, H; Graham, DY; Ji, Y; Li, D; Liang, X; Liu, M; Liu, W; Long, X; Lu, H; Song, Y; Sun, Y; Xu, B; Xu, G; Yu, L; Zhang, W; Zhao, Y	1
Fu, W; Song, Z; Zhou, L	1
Jin, Z; Li, Y; Lin, D; Lin, L; Meng, F; Pan, J; Shi, Z; Wu, J; Yang, N; Zhang, J; Zhou, Q	1
Lee, YC; Liou, JM; Wu, MS	1
Cogdill, AG; Guevara, B	1
Alcaide, N; Areia, M; Ariño, I; Axon, T; Barrio, J; Bordin, D; Boyanova, L; Brglez Jurecic, N; Bujanda, L; Buzas, G; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernández, M; Dominguez-Cajal, M; Garre, A; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Kunovský, L; Kupcinskas, L; Lamy, V; Leja, M; Lerang, F; Lucendo, A; Marcos Pinto, R; María Botargues Bote, J; Mégraud, F; Milosavljevic, T; Modolell, I; Niv, Y; Nyssen, OP; O'Morain, C; Ortuño, J; Pérez Lasala, J; Pérez-Aisa, Á; Perona, M; Phull, P; Przytulski, K; Rodrigo-Sáez, L; Rokkas, T; Romero, PM; Shvets, O; Simsek, I; Tepes, B; Tonkic, A; Venerito, M; Voynovan, I	1
Bazzoli, F; Frazzoni, L; Fuccio, L; Marasco, G; Zagari, RM	1
Hu, JN; Ji, CR; Ji, R; Li, LX; Li, YQ; Li, YY; Lin, MJ; Liu, J; Qiao, C; Qu, JY; Zuo, XL	1
Chang, YL; Hsu, PI; Kim, SE; Liou, WS; Shiu, SI; Tu, YK; Tung, YC; Wu, MF; Yang, JC; Yeh, HZ	1
Brglez Jurecic, N; Espada Sanchez, M; Gisbert, J; Mégraud, F; O'Morain, C; Perez Nyssen, O; Tepes, B; Tepes, K	1
Chen, H; Huang, K; Jin, D; Kong, S; Ye, F; Zhang, G	1
De Francesco, V; Fiorini, G; Gatta, L; Manta, R; Saracino, IM; Vaira, D; Zullo, A	1
Alaa Eddin, K; Alassi, MW; Alhalabi, M; Cheha, K	1
Dao, HV; Dao, LV; Dat, VQ; Hoang, LB; Nguyen, HT; Nguyen, HTV; Nguyen, TD; Tran, ATN; Vu, VT	1
Areia, M; Barrio, J; Beglinger, C; Bordin, D; Boyanova, L; Bujanda, L; Buzas, GM; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernandez, M; Doulberis, M; Fernandez-Salazar, L; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Jurecic, NB; Kunovský, L; Kupčinskas, J; Lamy, V; Lanas, A; Lasala, JP; Leja, M; Lerang, F; Lucendo, AJ; Marcos-Pinto, R; Marlicz, W; Megraud, F; Milivojevic, V; Molina-Infante, J; Morain, CO; Niv, Y; Nyssen, OP; Ortuño, J; Pérez Aísa, Á; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Sarsenbaeva, AS; Shvets, O; Simsek, I; Smith, S; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzhanina, L; Voynovan, I	1
Continisio, A; D'Abramo, FS; Di Leo, A; Ierardi, E; Losurdo, G; Piazzolla, M; Pricci, M; Rima, R	1
Hsu, PI; Kao, J; Lin, MH; Shie, CB; Tsay, FW; Wang, JW; Wu, DC; Wu, IT	1
Fan, J; Guo, H; Liang, X; Liu, E; Liu, J; Xia, Q; Zhao, Y	1
Bair, MJ; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; El-Omar, EM; Fang, YJ; Hsu, YC; Hu, WH; Jiang, XT; Kuo, CC; Lee, JY; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Wu, MS; Yang, TH; Yu, CC	1
Niu, Z; Ren, X; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L	1
Chehter, EZ; de Moraes Andrade, PV; Monteiro, YM	1
Chua, EG; Gao, X; Han, X; Lai, B; Marshall, BJ; Tay, CY; Wang, X; Wei, X; Yu, X; Zhang, X	1

Reviews

22 review(s) available for bismuth and levofloxacin

Article	Year
Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Alimentary pharmacology & therapeutics, 2006, Jan-01, Volume: 23, Issue:1 Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Ofloxacin; Treatment Failure	2006
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. The American journal of gastroenterology, 2006, Volume: 101, Issue:3 Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline	2006
Helicobacter pylori eradication therapy. Future microbiology, 2010, Volume: 5, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Ranitidine; Tetracycline; Treatment Failure; Treatment Outcome	2010
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wiener klinische Wochenschrift, 2010, Volume: 122, Issue:13-14 Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Proton Pump Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Retreatment	2010
A new look at anti-Helicobacter pylori therapy. World journal of gastroenterology, 2011, Sep-21, Volume: 17, Issue:35 Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Tetracycline	2011
[Helicobacter pylori - 2012]. Orvosi hetilap, 2012, Sep-09, Volume: 153, Issue:36 Topics: Algorithms; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Emigrants and Immigrants; Endoscopy, Gastrointestinal; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Hungary; In Situ Hybridization, Fluorescence; Levofloxacin; Ofloxacin; Peptic Ulcer; Polymerase Chain Reaction; Stomach Neoplasms	2012
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:7 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Treatment Failure	2013
Second and third line treatment options for Helicobacter pylori eradication. World journal of gastroenterology, 2014, Feb-14, Volume: 20, Issue:6 Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors	2014
Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. World journal of gastroenterology, 2014, May-21, Volume: 20, Issue:19 Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Polymerase Chain Reaction; Proton Pump Inhibitors; Treatment Outcome	2014
Helicobacter pylori. Current opinion in gastroenterology, 2014, Volume: 30, Issue:6 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms	2014
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology, 2016, Volume: 151, Issue:1 Topics: Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Canada; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline	2016
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs, 2017, Volume: 77, Issue:7 Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Proton Pump Inhibitors; Quinolones	2017
[Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of Zhonghua nei ke za zhi, 2017, May-01, Volume: 56, Issue:5 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Novel and Effective Therapeutic Regimens for Frontiers in cellular and infection microbiology, 2017, Volume: 7 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Mutation; Prevalence; Probiotics; Proton Pump Inhibitors; Pyrroles; Rifabutin; Sulfonamides; Tetracycline; Tetracycline Resistance	2017
Toward population specific and personalized treatment of Helicobacter pylori infection. Journal of biomedical science, 2018, Oct-02, Volume: 25, Issue:1 Topics: Algorithms; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Models, Theoretical	2018
Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology, 2019, Volume: 157, Issue:1 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Canada; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Tetracycline; United States	2019
Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:7 Topics: Anti-Bacterial Agents; Asia; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin	2020
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Digestive diseases and sciences, 2020, Volume: 65, Issue:7 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Biopsy; Bismuth; Breath Tests; Clarithromycin; Culture Techniques; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Feces; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Nitro Compounds; Organometallic Compounds; Peptic Ulcer; Polymerase Chain Reaction; Proton Pump Inhibitors; Rifabutin; Salicylates; Salvage Therapy; Serologic Tests; Stomach Neoplasms; Tetracycline; Thiazoles; Treatment Outcome; Urea	2020
Treatment of Helicobacter pylori infection: a clinical practice update. Minerva medica, 2021, Volume: 112, Issue:2 Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Meta-Analysis as Topic; Practice Guidelines as Topic; Probiotics; Proton Pump Inhibitors; Salvage Therapy; Systematic Reviews as Topic	2021
Efficacy of second-line regimens for BMJ open gastroenterology, 2020, Volume: 7, Issue:1 Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Network Meta-Analysis; Outcome Assessment, Health Care; Practice Guidelines as Topic; Proton Pump Inhibitors; Quinolones; Randomized Controlled Trials as Topic; Tetracycline	2020
Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review. European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Rifabutin; Tetracycline; Treatment Failure	2021
Third-line and rescue therapy for refractory World journal of gastroenterology, 2023, Jan-14, Volume: 29, Issue:2 Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Rifabutin; Tetracycline	2023

Trials

23 trial(s) available for bismuth and levofloxacin

Article	Year
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Alimentary pharmacology & therapeutics, 2003, Sep-15, Volume: 18, Issue:6 Topics: Adolescent; Adult; Aged; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Patient Compliance; Prospective Studies; Treatment Outcome	2003
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Alimentary pharmacology & therapeutics, 2003, Oct-15, Volume: 18, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Pantoprazole; Prospective Studies; Ranitidine; Sulfoxides; Tinidazole; Treatment Failure; Urea	2003
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. The American journal of gastroenterology, 2006, Volume: 101, Issue:2 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure	2006
Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure. Helicobacter, 2007, Volume: 12, Issue:1 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Ranitidine; Treatment Failure; Treatment Outcome	2007
First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Alimentary pharmacology & therapeutics, 2007, Aug-01, Volume: 26, Issue:3 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Ranitidine; Treatment Outcome	2007
Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter, 2013, Volume: 18, Issue:5 Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pilot Projects; Prospective Studies; Treatment Outcome; Urea; Young Adult	2013
Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter, 2014, Volume: 19, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Tetracycline; Time Factors; Treatment Outcome	2014
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:8 Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Urea	2015
Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scandinavian journal of gastroenterology, 2015, Volume: 50, Issue:10 Topics: Administration, Oral; Adult; Aged; Amoxicillin; Biopsy, Needle; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Failure; Treatment Outcome; Young Adult	2015
High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:10 Topics: Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Clarithromycin; Cytochrome P-450 CYP2C19; Dexlansoprazole; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Thailand	2015
Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine, 2017, Volume: 96, Issue:7 Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome	2017
Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection. Digestive diseases and sciences, 2017, Volume: 62, Issue:6 Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Cefuroxime; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Medication Adherence; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Failure; Urea	2017
Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. The American journal of gastroenterology, 2017, Volume: 112, Issue:9 Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Taiwan; Tetracycline; Treatment Outcome	2017
Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:2 Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors	2018
Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2017, Volume: 26, Issue:6 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Tetracycline; Young Adult	2017
Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial. Scientific reports, 2018, 06-13, Volume: 8, Issue:1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Exanthema; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Treatment Outcome	2018
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:11 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult	2019
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Frontiers of medicine, 2020, Volume: 14, Issue:1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome	2020
Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. Journal of digestive diseases, 2020, Volume: 21, Issue:10 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Treatment Outcome	2020
Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial. BMC infectious diseases, 2021, Jul-04, Volume: 21, Issue:1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomeprazole; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Syria; Tinidazole; Treatment Outcome; Young Adult	2021
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial. The lancet. Gastroenterology & hepatology, 2023, Volume: 8, Issue:3 Topics: Adult; Anti-Bacterial Agents; Australia; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; RNA, Ribosomal, 16S; Young Adult	2023
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Quinolones; Treatment Outcome	2023
Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy. Helicobacter, 2023, Volume: 28, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Polymerase Chain Reaction; Retrospective Studies; Treatment Outcome	2023

Other Studies

20 other study(ies) available for bismuth and levofloxacin

Article	Year
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. The American journal of gastroenterology, 2006, Volume: 101, Issue:8 Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Omeprazole; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure	2006
Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Digestive diseases and sciences, 2015, Volume: 60, Issue:2 Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Middle Aged; Omeprazole; Penicillins; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Rifabutin; Salvage Therapy; Spain; Tetracycline; Time Factors; Treatment Outcome	2015
Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance. Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:11 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Esomeprazole; Female; Humans; Levofloxacin; Male; Proton Pump Inhibitors	2015
Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second-line regimen in the presence of levofloxacin resistance--authors' reply. Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:11 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Esomeprazole; Female; Humans; Levofloxacin; Male; Proton Pump Inhibitors	2015
Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:11 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Bacterial; Barrett Esophagus; Bismuth; Breath Tests; Clarithromycin; Disease Management; Drug Therapy, Combination; Dyspepsia; Feces; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Italy; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms; Urea	2015
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:5 Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Outcome	2016
The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:4 Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Hospitals, Teaching; Humans; Levofloxacin; Logistic Models; Macrolides; Male; Middle Aged; Multivariate Analysis; Republic of Korea; Retrospective Studies; Tertiary Care Centers	2016
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American journal of gastroenterology, 2017, Volume: 112, Issue:2 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure	2017
The diagnosis and management of H. pylori infection in Singapore. Singapore medical journal, 2017, Volume: 58, Issue:5 Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Singapore	2017
Is Double-Dose Esomeprazole With Bismuth Really Safe? The American journal of gastroenterology, 2017, Volume: 112, Issue:12 Topics: Bismuth; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors	2017
Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology, 2018, Volume: 155, Issue:1 Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Incidence; Levofloxacin; Male; Middle Aged; Protective Factors; Proton Pump Inhibitors; Registries; Retrospective Studies; Risk Factors; Stomach Neoplasms	2018
Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin. BMC gastroenterology, 2019, Jul-25, Volume: 19, Issue:1 Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Cefuroxime; China; Drug Hypersensitivity; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Penicillins; Prospective Studies; Treatment Outcome	2019
Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg). Helicobacter, 2020, Volume: 25, Issue:3 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Hypersensitivity; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Registries; Tetracycline	2020
Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management. Digestive diseases (Basel, Switzerland), 2021, Volume: 39, Issue:4 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Health Plan Implementation; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries; Slovenia	2021
Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report. Medicine, 2021, Mar-12, Volume: 100, Issue:10 Topics: Anti-Bacterial Agents; Bismuth; DNA, Bacterial; Drug Hypersensitivity; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Middle Aged; Penicillins; Recurrence; Retreatment; Treatment Outcome	2021
Helicobacter pylori infection and eradication outcomes among Vietnamese patients in the same households: Findings from a non-randomized study. PloS one, 2021, Volume: 16, Issue:11 Topics: Adolescent; Adult; Antacids; Anti-Bacterial Agents; Asian People; Bismuth; Child; Drug Therapy, Combination; Family Characteristics; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Tetracycline; Vietnam; Young Adult	2021
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022, Volume: 20, Issue:10 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Penicillins; Prospective Studies; Proton Pump Inhibitors; Quinolones; Registries; Tetracycline	2022
Second-line Therapy for Helicobacter Pylori Eradication: State of the Art. Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:19 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline	2022
The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience. Journal of gastroenterology and hepatology, 2022, Volume: 37, Issue:10 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Treatment Outcome	2022
Effective photodegradation of rhodamine B and levofloxacin over CQDs modified BiOCl and BiOBr composite: Mechanism and toxicity assessment. Journal of colloid and interface science, 2022, Volume: 627 Topics: Anti-Bacterial Agents; Bismuth; Carbon; Catalysis; Environmental Pollutants; Levofloxacin; Photolysis; Quantum Dots; Rhodamines	2022